Alzheimer’s Drugs and NHS Access | The Daily Round
The UK’s fastest-growing news and insight platform for the care sector.

Looking for something specific? Try a search…

UK News

Latest Health & Social Care News

Stay up to date with the latest health and social care news from across the UK. From children’s mental health crisis and new inspection guidance for prison education to women’s mental health after childbirth and employment reforms affecting UK employers, discover the stories and developments shaping the sector.

Campaigners Urge NHS Access to New Alzheimer’s Treatments

Image for illustrative purposes only and may not depict the people, service or location featured in this article.

Former prime minister Lord Cameron has joined dementia specialists and former health ministers in calling for two Alzheimer’s medicines to become available through the NHS.

Lecanemab and donanemab are designed for people with mild cognitive impairment or early-stage dementia caused by Alzheimer’s disease. Both medicines have been licensed for use in Britain by the Medicines and Healthcare products Regulatory Agency but are not routinely funded by the NHS.

Clinical trials found that the treatments can slow the progression of symptoms in some eligible patients, but they do not cure or reverse Alzheimer’s disease. Treatment also requires specialist testing, regular infusions and monitoring because potentially serious side effects can include swelling or bleeding in the brain.

NICE previously concluded in draft guidance that the benefits did not justify the drugs’ overall cost to the health service. Appeals led to both treatments being reconsidered, and their appraisals remain in progress. This means it would be inaccurate to describe them as finally rejected or approved for routine NHS use.

Lord Cameron, now president of Alzheimer’s Research UK, is among 49 specialists and former ministers pressing for a solution. Suggestions include changing how dementia treatments are assessed or establishing a dedicated fund allowing controlled NHS access while further evidence is collected.

The group is also calling for a maximum 18-week wait for a dementia diagnosis. Earlier diagnosis would be essential if the medicines are recommended because they are intended for people in the early stages of Alzheimer’s and require confirmation of amyloid in the brain before treatment can begin.

Stay informed with the stories shaping health and social care.

Register with The Daily Round for the latest sector news, inspections & reports, wellbeing content, workforce insights, expert features and practical updates—delivered free to your inbox.

Posted by:
Mehala
Editorial Assistant – The Daily Round

Everything You Need. In Bite-Sized Updates

Busy day? We’ve got you covered. Get FREE daily news, practical insights, opportunities and wellbeing content, carefully curated for busy health and social care professionals. Just enter your details below to get The Daily Briefing delivered straight to your inbox.

Your Information
Your Interests
By subscribing, you agree to receive emails from The Daily Round, including news, updates and other relevant communications. Your information will be processed in accordance with our Privacy Policy and Terms of Use. You can unsubscribe at any time.

Sign up to our daily briefing

You can unsubscribe at any time. Please refer to our Policies for more information.

Everything You Need. In Bite-Sized Updates

Busy day? We’ve got you covered. Get FREE daily news, practical insights, opportunities and wellbeing content, carefully curated for busy health and social care professionals. Just enter your details below to get The Daily Briefing delivered straight to your inbox.

Your Information
Your Interests
By subscribing, you agree to receive emails from The Daily Round, including news, updates and other relevant communications. Your information will be processed in accordance with our Privacy Policy and Terms of Use. You can unsubscribe at any time.